Adjunct Professor in School of Medicine, Tongji University
CEO of Shanghai YaKe Biotechnology Ltd
Dr. Alex H. Chang is currently an Adjunct Professor in School of Medicine, Tongji University, and CEO of Shanghai YaKe Biotechnology Ltd., a R&D company dedicating to cancer cellular immunotherapy. Dr. Chang is also Associate Director of Shanghai Immunology Association Branch of Immunogenetics, Group Leader and Committee Member of the CAR-T19 Cell Research Group, Chinese Research Hospital Association Branch of Biotherapy, as well as Council Member of The Asia-Pacific Consortium of Gene and Cell Therapy.
Dr. Chang obtained his Medical degree from Capital University of Medical Sciences, and his PhD degree from University of British Columbia, Canada. He worked as Postdoctoral Trainee and Senior Scientist thereafter in Weill Medical College of Cornell University and Memorial Sloan-Kettering Cancer Center, specializing in gene therapy and cancer cellular immunotherapy.
Since coming back to China a few years ago, he was elected as a Member of the Pujiang Talent of Shanghai in 2012. His research has been supported by National Natural Science Foundation of China, Project 973 of National Science and Technology of China, as well as Prevention and Management of Major Chronic Non-Infectious Diseases Project of National Science and Technology of China. His research has been focused on cell-based cancer immunotherapy. His research group has established a platform technology for evaluation of chimeric antigen receptor-T cells against cancer, and is currently participating in clinical trials for the treatment of various hematological malignancies. His representative research work was published in Leukemia, Molecular Therapy, Nature Medicine, Nature Biotechnology and so on.